Clinical trial
A Phase 2a Trial of Avelumab, an Anti-PDL1 Antibody, in Relapsed and Refractory Peripheral T-cell Lymphoma
NCT03046953 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a Trial of Avelumab, an Anti-PDL1 Antibody, in Relapsed and Refractory Peripheral T-cell Lymphoma
- Lead sponsor
- University of Birmingham
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 8, 2017
- Completion date
- July 27, 2021
- Enrollment
- 35 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
t-cell lymphoma refractory, t-cell lymphoma relapsed